Search

Your search keyword '"Goto, Koichi"' showing total 1,635 results

Search Constraints

Start Over You searched for: Author "Goto, Koichi" Remove constraint Author: "Goto, Koichi"
1,635 results on '"Goto, Koichi"'

Search Results

51. Clinical Indicators to Guide Reoperation for Postoperative Hemorrhage After Pulmonary Resection for Malignancy: A Single-Institutional Experience of 22 Cases

52. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses

55. Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.

57. Clinical Indicators to Guide Reoperation for Postoperative Hemorrhage After Pulmonary Resection for Malignancy: A Single-Institutional Experience of 22 Cases.

61. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

62. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

63. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

65. Figure S1 from Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma

66. Table S2 from Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma

69. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

70. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

72. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non–Small Cell Lung Carcinoma

76. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

77. O7-3 Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC): Barossa study

78. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

80. A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a with G6PC c.648G>T

81. Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)

84. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

87. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

89. Metabolic hallmarks for purine nucleotide biosynthesis in small-cell lung carcinoma

90. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies

91. The prognostic impact of a high number of peritumoral alveolar macrophages in neuroendocrine carcinoma in the lung

92. Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

93. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

95. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

97. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

98. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

Catalog

Books, media, physical & digital resources